Modulation of the Extent of Ischemic Brain Damage by Protecting the Endothelial Glycocalyx with Low-Dose Albumin Administration (MOZEG)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509261-20-00

Acronym

MOZEG

Enrollment

100

Registered

2025-03-26

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Brief summary

Concentration of syndecan-1 in blood serum, Concentration of GAG in urine.

Detailed description

Mortality of enrolled patients on Day 90, Size of the ischemic brain lesion in patients with iCMP after low-dose albumin administration on control CT (MRI in exceptional cases)., Modified Rankin Scale (mRS) scores before the onset of iCMP and on Day 90., Neurological examination scores at screening and on Day 7/before discharge/transfer from the hospital

Interventions

DRUGSodium chloride Fresenius Kabi 0

DRUG9% infuzní roztok

DRUGHUMAN ALBUMIN SOLUTION

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Concentration of syndecan-1 in blood serum, Concentration of GAG in urine.	—

Secondary

Measure	Time frame
Mortality of enrolled patients on Day 90, Size of the ischemic brain lesion in patients with iCMP after low-dose albumin administration on control CT (MRI in exceptional cases)., Modified Rankin Scale (mRS) scores before the onset of iCMP and on Day 90., Neurological examination scores at screening and on Day 7/before discharge/transfer from the hospital	—

Countries

Czechia

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026